Compounders Research Compare

Estrella Immunopharma, Inc.(ESLA)

Biotechnology · EmeryVille, CA

$0.44-0.00 (-0.93%)

Delayed quote: Oct 6, 2026, 12:21 PM EDT

About Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.

EmeryVille, CA

3 employees

www.estrellabio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Cheng Liu

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T16:26:41.565Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:26:41.565Z.

Quote observation: 2026-10-06T16:21:33.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 18,597,773
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 146,670
TTM free cash flow · period ending 2026-06-30: -9,383,567

FMP input reference: 2d15fccd73dd71321fa30efb235d10704747171fee005d1a5dd6499fafc6c703

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ESLA EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

ESLA Competitors' EV/FCF Ratio

Estrella Immunopharma, Inc.

Current

Market Cap

$18.60M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Neuphoria Therapeutics Inc.

Market Cap

$18.86M

EV/FCF Ratio

N/A

TTM Avg

281.92x

3Y Avg

1403.45x

5Y Avg

1403.45x

NextCure, Inc.

Market Cap

$19.25M

EV/FCF Ratio

N/A

TTM Avg

232.26x

3Y Avg

232.26x

5Y Avg

232.26x

Cosmos Health Inc.

Market Cap

$17.64M

EV/FCF Ratio

N/A

TTM Avg

14.44x

3Y Avg

40.11x

5Y Avg

40.11x

P3 Health Partners Inc.

Market Cap

$19.66M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Actuate Therapeutics Inc

Market Cap

$20.03M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Lipocine Inc.

Market Cap

$17.15M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Marker Therapeutics, Inc.

Market Cap

$17.01M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PAVmed Inc.

Market Cap

$16.98M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Palatin Technologies, Inc.

Market Cap

$16.76M

EV/FCF Ratio

N/A

TTM Avg

2075.17x

3Y Avg

2570.19x

5Y Avg

2570.19x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Estrella Immunopharma, Inc. (ESLA)	$18.60M	N/A	N/A	N/A	N/A
Neuphoria Therapeutics Inc. (NEUP)vs ›	$18.86M	N/A	281.92x	1403.45x	1403.45x
NextCure, Inc. (NXTC)vs ›	$19.25M	N/A	232.26x	232.26x	232.26x
Cosmos Health Inc. (COSM)vs ›	$17.64M	N/A	14.44x	40.11x	40.11x
P3 Health Partners Inc. (PIII)vs ›	$19.66M	N/A	N/A	N/A	N/A
Actuate Therapeutics Inc (ACTU)vs ›	$20.03M	N/A	N/A	N/A	N/A
Lipocine Inc. (LPCN)vs ›	$17.15M	N/A	N/A	N/A	N/A
Marker Therapeutics, Inc. (MRKR)vs ›	$17.01M	N/A	N/A	N/A	N/A
PAVmed Inc. (PAVM)vs ›	$16.98M	N/A	N/A	N/A	N/A
Palatin Technologies, Inc. (PTN)vs ›	$16.76M	N/A	2075.17x	2570.19x	2570.19x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics